Table 4. Patient summary.
| Patient* | Gender / age,* (y) | Comorbidities | Glaucoma | Primary tumor | uRND | Adjuvant therapy | Post-uRND IOP*** | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | HTN | Diagnosis | Mean F/U IOP** | Location | Diagnosis | Laterality | Extent | Chemotherapy | Radiation therapy | OD | OS | ||||
| OD | OS | OD | OS | ||||||||||||
| 1 | M / 56 | + | - | POAG | POAG | 16.6 | 16.9 | Thyroid | Papillary carcinoma | OD | RND | - | - | 20.4 | 17.0 |
| 2 | M / 58 | + | + | POAG | POAG | 14.1 | 12.6 | Oropharynx | Squamous cell carcinoma | OD | RND | + | + | 16.1 | 12.6 |
| 3 | M / 66 | - | - | POAG | POAG | 14.3 | 12.7 | Thyroid | Papillary carcinoma | OD | RND | + | - | 15.4 | 13.7 |
| 4 | M / 44 | - | - | POAG | POAG | 15.7 | 15.3 | Tongue | Squamous cell carcinoma | OD | RND | + | - | 18.9 | 16.3 |
| 5 | F / 47 | - | - | POAG | POAG | 17.5 | 17.5 | Thyroid | Papillary carcinoma | OD | Modified RND | + | - | 19.9 | 17.8 |
| 6 | F / 50 | - | - | POAG | POAG | 13.6 | 14.6 | Thyroid | Papillary carcinoma | OD | RND | + | - | 15.2 | 15.0 |
| 7 | M / 59 | + | + | POAG | POAG | 13.2 | 12.2 | Thyroid | Papillary carcinoma | OD | Modified RND | + | - | 15.0 | 12.0 |
| 8 | F / 56 | + | - | POAG | POAG | 14.4 | 14.9 | Thyroid | Squamous cell carcinoma | OS | Modified RND | + | - | 13.8 | 17.3 |
| 9 | F / 55 | - | - | POAG | POAG | 14.5 | 14.5 | Thyroid | Papillary carcinoma | OS | RND | - | - | 14.1 | 16.9 |
| 10 | M / 58 | + | + | POAG | POAG | 12.1 | 12.9 | Thyroid | Papillary carcinoma | OS | Modified RND | + | - | 12.1 | 13.8 |
| 11 | M / 53 | - | - | POAG | POAG | 14.0 | 14.8 | Thyroid | Papillary carcinoma | OS | Modified RND | + | - | 13.6 | 19.2 |
| 12 | M / 59 | - | - | GS | GS | 16.3 | 15.9 | Thyroid | Papillary carcinoma | OD | Modified RND | - | - | 15.9 | 15.7 |
| 13 | M / 63 | + | - | GS | GS | 14.9 | 14.1 | Oropharynx | Squamous cell carcinoma | OD | RND | + | - | 14.6 | 14.1 |
| 14 | F / 65 | + | + | GS | GS | 19.6 | 19.2 | Thyroid | Squamous cell carcinoma | OD | Modified RND | + | - | 20.2 | 19.0 |
| 15 | F / 49 | - | - | GS | GS | 18.4 | 18.2 | Thyroid | Papillary carcinoma | OS | RND | - | - | 18.7 | 18.6 |
| 16 | M / 55 | - | - | GS | GS | 18.7 | 18.8 | Thyroid | Papillary carcinoma | OS | Modified RND | + | - | 18.5 | 19.2 |
| 17 | M / 54 | - | - | GS | GS | 13.0 | 14.1 | Thyroid | Squamous cell carcinoma | OS | Modified RND | + | - | 13.1 | 15.0 |
| 18 | M / 56 | - | + | GS | GS | 19.4 | 19.7 | Thyroid | Papillary carcinoma | OS | Modified RND | + | - | 19.3 | 20.3 |
* Age at operation.
** Mean treat-IOP for glaucoma patients and mean untreat-IOP for glaucoma suspects.
*** Mean IOP during the post-op 6 months.
DM, diabetes mellitus; HTN, hypertension; OD, oculus dexter; OS, oculus sinister; uRND, unilateral radical neck dissection; LN, lymph node; POAG, primary open-angle glaucoma; GS, glaucoma suspect.